Using triple antiplatelet therapy in patients with non-ST elevation acute coronary syndrome managed invasively: A cost-effectiveness analysis

Value in Health

Volumn 11, Issue 5, 2008, Pages 853-861

  Latour Pérez, Jaime ^a   De Miguel Balsa, Eva ^a   Betegón, Lourdes ^b   Badia, Xavier ^b  

^a HOSPITAL GENERAL UNIVERSITARIO DE ELCHE   (Spain)

^b IQVIA   (United States)

Author keywords

Acute coronary syndrome; Clopidogrel; Cost effectiveness; Glycoprotein IIb IIIa inhibitors

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; CLOPIDOGREL; EPTIFIBATIDE; TIROFIBAN;

ACUTE CORONARY SYNDROME; ANGIOPLASTY; ARTICLE; BLEEDING; CARDIOVASCULAR RISK; CATHETERIZATION; CLINICAL TRIAL; CORONARY ARTERY DISEASE; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DRUG EFFICACY; HEALTH CARE SYSTEM; HEART INFARCTION; HUMAN; LIFESPAN; MONOTHERAPY; PRIORITY JOURNAL; PROBABILITY; QUALITY ADJUSTED LIFE YEAR; RISK FACTOR; RISK REDUCTION; ST SEGMENT ELEVATION; TRANSIENT ISCHEMIC ATTACK;

EID: 52649159273     PISSN: 10983015     EISSN: 15244733     Source Type: Journal    
DOI: 10.1111/j.1524-4733.2008.00338.x     Document Type: Article

References (45)

1. Bosch X, Marrugat J. Platelet glycoprotein IIb/IIIa blockers for percutaneous coronary revascularization, and unstable angina and non-ST-segment elevation myocardial infarction. Cochrane Database Syst Rev 2001 4 : CD002130.
2. Choudhry NK, Singh JM, Barolet A, et al. How should patients with unstable angina and non-ST-segment elevation myocardial infarction be managed? A meta-analysis of randomized trials. Am J Med 2005 118 : 465 74.
3. Bassand JP, Hamm CW, Ardissino D, et al. Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes. The Task Force for the Diagnosis and Treatment of Non-ST-Segment Elevation Acute Coronary Syndromes of the European Society of Cardiology. Eur Heart J 2007 28 : 1598 660.
4. Anderson JL, Adams CD, Antman EM, et al. ACC/AHA 2007 guidelines for the management of patients with unstable Angina/non ST-elevation myocardial infarction. Circulation 2007 116 : 803 77.
5. ICSI. Diagnosis and treatment of chest pain and acute coronary syndrome (ACS). Institute for clinical systems improvement. Available from: http://www.icsi.org/acs_acute_coronary_syndrome/ acute_jcoronary_syndrome_and_chest_pain [Accessed March 4, 2007].
6. Smith SC, Jr, Feldman TE, Hirshfeld JW Jr, et al. ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update 2001 Guidelines for Percutaneous Coronary Intervention). Circulation 2006 113 : e166 286.
7. Robinson M, Palmer S, Sculpher M, et al. Cost-effectiveness of alternative strategies for the initial medical management of non-ST elevation acute coronary syndrome: systematic review and decision-analytical modelling. Health Technol Assess 2005 9 : iii xi.
8. Kastrati A, Mehilli J, Neumann FJ, et al. Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment: the ISAR-REACT 2 randomized trial. JAMA 2006 295 : 1531 8.
9. Latour-Pérez J, De-Miguel-Balsa E, Alcalá-López A, Coves-Orts FJ. Efectividad y seguridad de la "triple antiagregació n" en pacientes sometidos a intervencionismo coronario. Med Intensiva 2007 31 : 220 30.
10. Glaser R, Glick HA, Herrmann HC, Kimmel SE. The role of risk stratification in the decision to provide upstream versus selective glycoprotein IIb/IIIa inhibitors for acute coronary syndromes: a cost-effectiveness analysis. J Am Coll Cardiol 2006 47 : 529 37.
11. Stone GW, Bertrand ME, Moses JW, et al. Routine upstream initiation vs deferred selective use of glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: the ACUITY timing trial. JAMA 2007 297 : 591 602.
12. Yusuf S, Mehta SR, Chrolavicius S, et al. Comparison of fondaparinux and enoxaparin in acute coronary syndromes. N Engl J Med 2006 354 : 1464 76.
13. Instituto Nacional de Estadística. Indice de precios al consumo. INE. Available from: http://www.ine.es/daco/ipc.htm [Accessed February 25, 2007].
14. Weinstein MC, Siegel JE, Gold MR, et al. Recommendations of the Panel on Cost-effectiveness in Health and Medicine. JAMA 1996 276 : 1253 8.
15. Antman EM, Cohen M, Bernink PJ, et al. The TIMI risk score for unstable angina/non-ST elevation MI. A method for prognostication and therapeutic decision making. JAMA 2000 284 : 835 42.
16. Mehta SR, Yusuf S, Peters RJ, et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 2001 358 : 527 33.
17. Steinhubl SR, Berger PB, Mann JT, III., et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA 2002 288 : 2411 20.
18. Mark DB, Hlatky MA, Califf RM, et al. Cost-effectiveness of thrombolytic therapy with tissue plasminogen activator as compared with streptokinase for acute myocardial infarction. N Engl J Med 1995 332 : 1418 24.
19. Mark DB, Harrington RA, Lincoff AM, et al. Cost-effectiveness of platelet glycoprotein IIb/IIIa inhibition with eptifibatide in patients with non-ST-elevation acute coronary syndromes. Circulation 2000 101 : 366 71.
20. Cequier A, Moris C, Badia X, Lara N. Análisis de minimización de costes de bivaluridina versus heparina más abciximab en pacientes sometidos a intervención coronaria percutánea. Rev Esp Econ Salud 2006 5 : 168 76.
21. Badia X, Bueno H, Gonzalez J, Jr, et al. Análisis de la relación coste-efectividad a corto y largo plazo de clopidogrel añadido a terapia estándar en pacientes con syndrome coronario agudo en España. Rev Esp Cardiol 2005 58 : 1385 95.
22. Oliva G, Espallargues M, Pons JM. Stents recubiertos de fármacos antiproliferativos: revision sistemática del beneficio y estimación del impacto presupuestario. Rev Esp Cardiol 2004 57 : 617 28.
23. Russell S, Antonanzas F, Mainar V. Impacto económico del stent coronario Taxus: implicaciones para el sistema sanitario español. Rev Esp Cardiol 2006 59 : 889 96.
24. Kalish SC, Gurwitz JH, Krumholz HM, Avorn J. A cost-effectiveness model of thrombolytic therapy for acute myocardial infarction. J Gen Intern Med 1995 10 : 321 30.
25. Eckman MH, Levine HJ, Salem DN, Pauker SG. Making decisions about antithrombotic therapy in heart disease: decision analytic and cost-effectiveness issues. Chest 1998 114 (Suppl. 5 S699 714.
26. Kuntz KM, Tsevat J, Goldman L, Weinstein MC. Cost-effectiveness of routine coronary angiography after acute myocardial infarction. Circulation 1996 94 : 957 65.
27. Sonnenberg FA, Beck JR. Markov models in medical decision making: a practical guide. Med Decis Making 1993 13 : 322 38.
28. Ministerio de Sanidad y Consumo. Tasas de Mortalidad por 100.000 habitantes por edad y sexo. MSC. Available from: http://www.msc.es/ estadEstudios/estadisticas/estadisticas/estMinisterio/mortalidad/docs/Tabla_1.2. xls [Accessed March 4, 2007].
29. Rao SV, Jollis JG, Harrington RA, et al. Relationship of blood transfusion and clinical outcomes in patients with acute coronary syndromes. JAMA 2004 292 : 1555 62.
30. Beck JR, Pauker SG, Gottlieb JE, et al. A convenient approximation of life expectancy (the "DEALE"). II. Use in medical decision-making. Am J Med 1982 73 : 889 97.
31. Mueller C, Neumann FJ, Perruchoud AP, Buettner HJ. Renal function and long term mortality after unstable angina/non-ST segment elevation myocardial infarction treated very early and predominantly with percutaneous coronary intervention. Heart 2004 90 : 902 7.
32. Allen LA, O'Donnell CJ, Camargo CA Jr., et al. Comparison of long-term mortality across the spectrum of acute coronary syndromes. Am Heart J 2006 151 : 1065 71.
33. Lim MJ, Spencer FA, Gore JM, et al. Impact of combined pharmacologic treatment with clopidogrel and a statin on outcomes of patients with non-ST-segment elevation acute coronary syndromes: perspectives from a large multinational registry. Eur Heart J 2005 26 : 1063 9.
34. Herlitz J, Karlson BW, Sjolin M, Lindqvist J. Ten year mortality in subsets of patients with an acute coronary syndrome. Heart 2001 86 : 391 6.
35. Hunink M, Glasziou P. Variability and uncertainty. In : Humink M, Glasziou P, eds. Decision Making in Health and Medicine. Integrating Evidence and Values. Cambridge : Oxford University Press, 2001.
36. Hunink M, Glasziou P. Constrained Resources. Decision Making in Health and Medicine. Integrating Evidence and Values. Cambridge : Cambridge University Press, 2001.
37. Brown R, Armstrong P. Cost effectiveness in Canada of eptifibatide treatment for acute coronary syndrome patients using PURSUIT subgroup analysis. Can J Cardiol 2003 19 : 161 6.
38. Hillegass WB, Newman AR, Raco DL. Glycoprotein IIb/IIIa receptor therapy in percutaneous coronary intervention and non-ST-segment elevation acute coronary syndromes. Estimating the economic implications. Pharmacoeconomics 2001 19 : 41 55.
39. Palmer S, Sculpher M, Philips Z, et al. Management of non-ST-elevation acute coronary syndromes: how cost-effective are glycoprotein IIb/IIIA antagonists in the UK National Health Service? Int J Cardiol 2005 100 : 229 40.
40. Plosker GL, Ibbotson T. Eptifibatide: a pharmacoeconomic review of its use in percutaneous coronary intervention and acute coronary syndromes. Pharmacoeconomics 2003 21 : 885 912.
41. Sacristan JA, Del Oliva J, LJ, et al. Qué es una tecnología sanitaria eficiente en España? Gac Sanit 2002 16 : 334 43.
42. Lyseng-Williamson KA, Plosker GL. Clopidogrel: a pharmacoeconomic review of its use in patients with non-ST elevation acute coronary syndromes. Pharmacoeconomics 2006 24 : 709 26.
43. Plosker GL, Lyseng-Williamson KA. Clopidogrel: a review of its use in the prevention of thrombosis. Drugs 2007 67 : 613 46.
44. Lincoff AM, Bittl JA, Harrington RA, et al. Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial. JAMA 2003 289 : 853 63.
45. Lincoff AM, Kleiman NS, Kereiakes DJ, et al. Long-term efficacy of bivalirudin and provisional glycoprotein IIb/IIIa blockade vs heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary revascularization: REPLACE-2 randomized trial. JAMA 2004 292 : 696 703.